Ruth Prieto1, José M Pascual2. 1. Department of Neurosurgery, Puerta de Hierro University Hospital, C/Manuel de Falla 1, Majadahonda, 28222, Madrid, Spain. rprieto29@hotmail.com. 2. Department of Neurosurgery, La Princesa University Hospital, Madrid, Spain.
Abstract
BACKGROUND: The growing interest in the molecular and genetic alterations of craniopharyngiomas (CPs) is embodied in recent studies revealing insights into the CP tumorigenesis and identifying novel molecular pathways amenable of targeted therapies. The actual impact of this new information, however, remains inconclusive. METHODS: We present a comprehensive review of the accumulated knowledge on molecular biology of CPs and a critical analysis on the strengths and weaknesses of the studies focused on CP molecular/genetic alterations published to date. RESULTS: A thorough analysis of the alterations of β-catenin/CTNNB1 and BRAF genes investigated in 1123 CP cases included in 27 studies, showed that, on average, CTNNB1 mutations were present in two-thirds of adamantinomatous CPs and BRAF mutations in 90% of papillary CPs. Their role as oncogenic drivers has not been well established. Although rare, coexistence of both mutations may occur. The involvement of pituitary stem cells in human CP tumorigenesis is still uncertain. Expression of stem markers in human CP samples predominantly occurred along the CP border in contact with brain tissue. Finally, none of the various molecular alterations which have been proposed as markers for CP recurrence can be used today as reliable predictors of the CP behavior. CONCLUSIONS: The isolated evaluation of CPs' molecular or genetic profiles that do not take into consideration fundamental pathological and therapeutic factors, specifically the tumor topography and the degree of tumor removal, may actually generate confusion regarding the reliability of some biomarkers to predict the CP biological behavior.
BACKGROUND: The growing interest in the molecular and genetic alterations of craniopharyngiomas (CPs) is embodied in recent studies revealing insights into the CP tumorigenesis and identifying novel molecular pathways amenable of targeted therapies. The actual impact of this new information, however, remains inconclusive. METHODS: We present a comprehensive review of the accumulated knowledge on molecular biology of CPs and a critical analysis on the strengths and weaknesses of the studies focused on CP molecular/genetic alterations published to date. RESULTS: A thorough analysis of the alterations of β-catenin/CTNNB1 and BRAF genes investigated in 1123 CP cases included in 27 studies, showed that, on average, CTNNB1 mutations were present in two-thirds of adamantinomatous CPs and BRAF mutations in 90% of papillary CPs. Their role as oncogenic drivers has not been well established. Although rare, coexistence of both mutations may occur. The involvement of pituitary stem cells in human CP tumorigenesis is still uncertain. Expression of stem markers in human CP samples predominantly occurred along the CP border in contact with brain tissue. Finally, none of the various molecular alterations which have been proposed as markers for CP recurrence can be used today as reliable predictors of the CP behavior. CONCLUSIONS: The isolated evaluation of CPs' molecular or genetic profiles that do not take into consideration fundamental pathological and therapeutic factors, specifically the tumor topography and the degree of tumor removal, may actually generate confusion regarding the reliability of some biomarkers to predict the CP biological behavior.
Authors: Bernd M Hofmann; Jürgen Kreutzer; Wolfgang Saeger; Michael Buchfelder; Ingmar Blümcke; Rudolf Fahlbusch; Rolf Buslei Journal: Am J Surg Pathol Date: 2006-12 Impact factor: 6.394
Authors: Carles Gaston-Massuet; Cynthia Lilian Andoniadou; Massimo Signore; Sujatha A Jayakody; Nicoletta Charolidi; Roger Kyeyune; Bertrand Vernay; Thomas S Jacques; Makoto Mark Taketo; Paul Le Tissier; Mehul T Dattani; Juan Pedro Martinez-Barbera Journal: Proc Natl Acad Sci U S A Date: 2011-06-02 Impact factor: 11.205
Authors: Cynthia Lilian Andoniadou; Danielle Matsushima; Seyedeh Neda Mousavy Gharavy; Massimo Signore; Albert Ian Mackintosh; Marie Schaeffer; Carles Gaston-Massuet; Patrice Mollard; Thomas Stanley Jacques; Paul Le Tissier; Mehul Tulsidas Dattani; Larysa Halyna Pevny; Juan Pedro Martinez-Barbera Journal: Cell Stem Cell Date: 2013-10-03 Impact factor: 24.633
Authors: Priscilla K Brastianos; Amaro Taylor-Weiner; Peter E Manley; Robert T Jones; Dora Dias-Santagata; Aaron R Thorner; Michael S Lawrence; Fausto J Rodriguez; Lindsay A Bernardo; Laura Schubert; Ashwini Sunkavalli; Nick Shillingford; Monica L Calicchio; Hart G W Lidov; Hala Taha; Maria Martinez-Lage; Mariarita Santi; Phillip B Storm; John Y K Lee; James N Palmer; Nithin D Adappa; R Michael Scott; Ian F Dunn; Edward R Laws; Chip Stewart; Keith L Ligon; Mai P Hoang; Paul Van Hummelen; William C Hahn; David N Louis; Adam C Resnick; Mark W Kieran; Gad Getz; Sandro Santagata Journal: Nat Genet Date: 2014-01-12 Impact factor: 38.330
Authors: Antonio Martínez-Ortega; Álvaro Flores-Martinez; Eva Venegas-Moreno; Elena Dios; Diego Del Can; Eloy Rivas; Ariel Kaen; Eugenio Cárdenas Ruiz-Valdepeñas; Elena Fajardo; Florinda Roldán; Natividad González-Rivera; Rosario Oliva; José Ignacio Fernández-Peña; Alfonso Soto-Moreno; David A Cano Journal: J Clin Med Date: 2022-01-05 Impact factor: 4.241
Authors: Jie Wu; Xiao Wu; You Qing Yang; Han Ding; Le Yang; You Yuan Bao; Lin Zhou; Chen Xing Yang; Tao Hong Journal: Neurosurg Rev Date: 2021-06-22 Impact factor: 2.800